3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Neoplasms
2
Mycosis Fungoides
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Interventions
Rituximab
4
Tacrolimus
3
fludarabine
2
cobomarsen
2
Peripheral Blood Stem Cell Transplantation
2
Ganciclovir
2
Etoposide
2
Cyclophosphamide
2
Busulfan
2
Antilymphocyte Serum
2
ruxolitinib
1
ponatinib
1
pomalidomide
1
ibritumomab tiuxetan
1
fludarabine phosphate
1
ferric carboxymaltose
1
epratuzumab
1
denileukin diftitox
1
dacetuzumab
1
beta-Glucans
1
arginine butyrate
1
Vorinostat
1
Vincristine
1
Valganciclovir
1
Stem Cell Transplantation
1
Sirolimus
1
Prednisone
1
Oxycodone
1
Mycophenolic Acid
1
Morphine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoproliferative Disorders
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled